Somatic Hypermutation, Immunoglobulin
"Somatic Hypermutation, Immunoglobulin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A programmed mutation process whereby changes are introduced to the nucleotide sequence of immunoglobulin gene DNA during development.
Descriptor ID |
D027041
|
MeSH Number(s) |
G05.558.810 G12.500.780
|
Concept/Terms |
Somatic Hypermutation, Immunoglobulin- Somatic Hypermutation, Immunoglobulin
- Hypermutation, Immunoglobulin Somatic
- Hypermutations, Immunoglobulin Somatic
- Immunoglobulin Somatic Hypermutations
- Somatic Hypermutations, Immunoglobulin
- Ig Somatic Hypermutation
- Immunoglobulin Somatic Hypermutation
- Hypermutation, Somatic, Immunoglobulin
- Somatic Hypermutation, Ig
- Hypermutation, Ig Somatic
- Hypermutations, Ig Somatic
- Ig Somatic Hypermutations
- Somatic Hypermutations, Ig
|
Below are MeSH descriptors whose meaning is more general than "Somatic Hypermutation, Immunoglobulin".
Below are MeSH descriptors whose meaning is more specific than "Somatic Hypermutation, Immunoglobulin".
This graph shows the total number of publications written about "Somatic Hypermutation, Immunoglobulin" by people in this website by year, and whether "Somatic Hypermutation, Immunoglobulin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Somatic Hypermutation, Immunoglobulin" by people in Profiles.
-
Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Comput Biol. 2016 05; 12(5):e1004940.
-
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.